Two sides of one coin.

Pathogen-agnostic early warning

We detect outbreaks by waiting for humans to get sick and show up at hospitals — weeks late, by design. Build the metagenomic sampling network that flags any novel replicating pathogen in days.

Why now

Sequencing cost fell below the threshold where continuous environmental metagenomics is economically routine.

The shape of it

A network of wastewater, airport, and air-handler samplers feeding a continuous metagenomic pipeline that alarms on any novel exponentially-growing genome — known or unknown.

Success looks like

Time-to-detection for a novel pathogen drops from weeks to days, globally, before the first hospital wave.

good quest

A real systems + bioinformatics frontier, decisive against the one risk that scales to civilization-ending, and good with no plausible misuse.

Days-not-months vaccine manufacturing

mRNA proved the design step can take hours. Manufacturing, fill-finish, and distribution still take a year. Build the distributed, rapidly-reconfigurable biomanufacturing stack that closes the gap.

Why now

Cell-free and benchtop synthesis matured; the constraint is now industrialization, not science.

The shape of it

Containerized, standardized micro-factories + a regulatory playbook that lets a validated process move from sequence to vialed doses in days, near the point of need.

Success looks like

A new vaccine reaches a billion arms within weeks of pathogen identification, not within years.

good quest

A genuine manufacturing + regulatory frontier, decisive in any fast pandemic, and unambiguously good.

Far-UVC as building infrastructure

We treat indoor airborne transmission as a fact of life. It is not — it is an untreated utility. Build the far-UVC + ventilation retrofit company that makes indoor air as safe as treated water.

Why now

Far-UVC safety data matured and 222nm excimer cost is on a manufacturing learning curve.

The shape of it

A retrofit + new-build company that designs, installs, and certifies far-UVC + ventilation for schools, transit, and offices, sold on insurance and absenteeism economics.

Success looks like

Airborne transmission indoors becomes as rare as cholera from tap water in developed economies.

good quest

An engineering frontier with massive everyday upside even absent a pandemic, and good with no downside.

Where to apply

Founders FundVenture Capitalapply →

best for: Scaling massive hard-tech quests, space, defense, biotech, fusion.

a16z American DynamismVenture Capitalapply →

best for: Founders rebuilding American industrial capacity.

Lux CapitalVenture Capitalapply →

best for: Technical founders at the frontier who need contrarian conviction capital.

hard tech

Energy abundance

$2T prize at the limit

The fission permitting unlock

The NRC takes years and tens of millions to license a reactor design that has already been built and run safely. The bottleneck is paperwork, not physics. Build the regulatory-tech company that compresses approval to months.

Why now

Post-2024 advanced-reactor legislation reopened the path; a generation of SMR designs is queued behind process, not engineering.

The shape of it

Software + regulatory expertise that productizes licensing: standardized design packages, automated safety-case generation, and a track record that compounds across applicants.

Success looks like

Time-and-cost to license a proven reactor design falls 10×, and firm clean baseload actually gets built.

good quest

A regulatory + systems frontier that gates the entire energy stack; unambiguously good if you believe cheap clean energy lifts every other quest.

Geothermal everywhere via oilfield tooling

The oil & gas industry already knows how to drill anywhere on Earth, cheaply. Redirect that exact capability into closed-loop geothermal and you get firm clean power on demand.

Why now

Directional drilling and downhole tooling hit a cost/perf point where engineered geothermal pencils out; displaced O&G crews are available.

The shape of it

A geothermal developer that acquires and redeploys oilfield drilling capacity, standardizes closed-loop well design, and sells firm power via PPA to data centers and grids.

Success looks like

Firm geothermal is deployable in most geographies at a cost competitive with gas peakers.

good quest

A real engineering + cost frontier, decisive for firm clean power, and good with negligible externalities.

Hundred-hour grid storage

Renewables are the cheapest electrons in history and worthless when the wind stops. Lithium is too expensive past ~8 hours. Build the long-duration storage company that makes 100-hour storage cost-competitive.

Why now

Iron-air, thermal, and mechanical approaches crossed from lab to first commercial deployments in 2024–26.

The shape of it

A storage developer + manufacturer betting on one chemistry/mechanism, selling multi-day firming to utilities under capacity contracts.

Success looks like

A renewables-plus-storage grid delivers firm power at a cost below new fossil generation.

good quest

A materials + systems frontier that determines whether cheap renewables become reliable power; unambiguously good.

Underwriting the interconnection queue

More clean energy is stuck waiting for a grid connection than exists on the grid today — 2,061 GW in the US queue alone, a median wait pushing five years — and the bottleneck is financial as much as technical: nobody underwrites the risk of a stuck queue position so it can be de-risked and resold. Build the company that buys, de-risks, and resells interconnection queue positions the way an infrastructure fund de-risks a permit.

Why now

PJM reopened its queue in 2026 after a multi-year freeze, and interconnection waits stretching up to 12 years for some load categories have turned queue position itself into a tradeable, underwritable asset rather than a paperwork formality.

The shape of it

A capital-plus-engineering entity that acquires stalled interconnection positions, applies flexible-interconnection engineering (curtailment agreements, non-firm capacity) to unstick them faster than a full network upgrade would, and sells construction-ready capacity to developers.

Success looks like

Time from interconnection application to commercial operation falls from five years toward one, unlocking gigawatts of already-financed clean generation sitting idle in queues today.

good quest

A real capital-markets-plus-grid-engineering frontier that is the actual bottleneck on the energy transition right now, not a hypothetical one, good with no credible downside.

Where to apply

1517 Fund · Medici ProjectGrantapply →

best for: Students, dropouts, and renegade builders with a prototype and no credentials, based in North America.

776 FellowshipFellowshipapply →

best for: Under-22 builders with spiky talent and a real project.

best for: Young climate-focused founders bridging activism and company building.

Activate FellowshipAcceleratorapply →

best for: Technical founders who need time and lab equipment, not just cash.

hard tech

Low-cost housing & construction

$300B prize at the limit

The factory-built housing company that actually scales

Modular construction has failed a dozen times — on logistics, financing, and entitlement, almost never on the technology. Build the vertically-integrated company that owns the whole failure surface.

Why now

A graveyard of modular startups produced a clear map of why they died; capital and software to fix logistics + financing now exist.

The shape of it

A vertically-integrated factory + entitlement + project-financing company that sells finished homes, not panels, and underwrites its own absorption risk.

Success looks like

Quality housing delivered at roughly one-third today’s cost per unit, repeatably, at metro scale.

good quest

A logistics + finance frontier disguised as a tech problem; decisive for 1.6B under-housed humans and unambiguously good.

Permitting and entitlement as an API

A single-family home waits months on discretionary review that produces no safety value. Build the software that turns zoning + permitting from a black box into a queryable, deterministic API.

Why now

Municipal records are digitizing and LLMs can finally parse zoning code reliably enough to be load-bearing.

The shape of it

A platform that ingests local code, returns by-right buildable envelopes instantly, auto-generates compliant submittals, and tracks the approval pipeline for builders and cities.

Success looks like

Time-to-permit for compliant housing falls from months to days in adopting jurisdictions.

good quest

An unglamorous software + govtech frontier with enormous leverage; good for builders, cities, and residents alike.

Where to apply

Activate FellowshipAcceleratorapply →

best for: Under-22 builders with spiky talent and a real project.

best for: Technical founders who need time and lab equipment, not just cash.

a16z American DynamismVenture Capitalapply →

best for: Founders rebuilding American industrial capacity.

Fifty YearsVenture Capitalapply →

best for: Mission-aligned technical founders who want to marry returns and impact.

progress & abundance

Pedagogy at scale

$300B prize at the limit

The Bloom 2-sigma tutor

1:1 tutoring beats classroom instruction by two standard deviations and has been unaffordable for 4,000 years. Build the AI tutor that delivers it for the marginal cost of inference, in any language.

Why now

Models crossed the threshold where they can diagnose a misconception and adapt — not just answer — at conversational latency and cost.

The shape of it

A tutoring product (not a chatbot) with a real pedagogical model: mastery tracking, spaced retrieval, Socratic dialog, and outcome measurement against standardized gains.

Success looks like

A median student using it gains the Bloom 2-sigma effect, reproducibly, on independent assessments.

good quest

A pedagogy + measurement frontier, civilization-scale if it works, and unambiguously good.

Credentialing that routes around the diploma

Employers want proof of skill; the degree is a $1.5T noisy proxy. Build the verifiable, adversarially-robust skills-assessment standard that employers actually trust.

Why now

AI both threatens take-home assessment integrity and enables proctored, adaptive, cheating-resistant evaluation at scale.

The shape of it

An assessment + credential issuer with employer-side validity studies, designed from day one to resist AI-assisted cheating and to be portable across employers.

Success looks like

A meaningful share of hiring uses the credential as a primary signal, decoupling opportunity from tuition.

good quest

A measurement + trust frontier; good if you believe opportunity should track skill, not the ability to pay for a degree.

Where to apply

1517 Fund · Medici ProjectGrantapply →

best for: Unproven people with a weird, specific idea and no credential path.

best for: Students, dropouts, and renegade builders with a prototype and no credentials, based in North America.

O'Shaughnessy FellowshipsFellowshipapply →

best for: Agency-specific builders whose project does not fit a discipline box.

Rise Fund (TPG)Venture Capitalapply →

best for: Growth-stage impact companies with measurable IMM.

welfare floor

Infectious disease (malaria, TB, HIV)

$200B prize at the limit

Single-encounter curatives for TB

Tuberculosis kills 1.3M people a year and the cure requires 4–6 months of daily adherence most patients cannot sustain. Build the long-acting or single-dose regimen plus the delivery model.

Why now

Long-acting injectable formulation science matured (proven in HIV PrEP); the same toolkit is unapplied to TB at scale.

The shape of it

A drug-delivery company pairing a long-acting regimen with a field delivery and adherence model designed for high-burden, low-resource settings.

Success looks like

TB treatment becomes a single supervised encounter, and TB mortality falls like HIV mortality did after ART.

good quest

A pharmacology + delivery frontier, decisive against humanity’s deadliest infection, and unambiguously good.

Safe, reversible gene-drive vector control

Bednets and spraying have plateaued; the mosquito is the delivery system for malaria. Build the safe, reversible, field-deployable gene-drive company for malaria vectors.

Why now

Gene-drive and self-limiting designs reached field-trial readiness; the gating problems are now governance and reversibility, which are buildable.

The shape of it

A vector-control company developing confinable/reversible drives plus the field-trial, regulatory, and community-consent apparatus to deploy them responsibly.

Success looks like

Malaria transmission collapses in deployment regions without ecological regret.

good quest

A genuine genetic-engineering frontier with real risk that must be engineered down; good if and only if reversibility is solved — which is the quest.

Point-of-care diagnostics under a dollar

You cannot treat what you cannot diagnose, and PCR needs a lab, cold chain, and a day. Build the paper or CRISPR diagnostic that returns an accurate result anywhere for pennies.

Why now

CRISPR-based detection (SHERLOCK/DETECTR-class) moved from papers to manufacturable formats.

The shape of it

A diagnostics company productizing instrument-free, ambient-stable tests for the high-burden infections, distributed through existing community-health rails.

Success looks like

Accurate infectious-disease diagnosis is available at the point of need anywhere on Earth for under a dollar.

good quest

A biotech + manufacturing frontier with enormous leverage on every other disease program; unambiguously good.

Where to apply

Deep Science VenturesVenture Studioapply →

best for: Founders who want a co-founder thesis and institutional support from day one.

Fifty YearsVenture Capitalapply →

best for: Mission-aligned technical founders who want to marry returns and impact.

Rise Fund (TPG)Venture Capitalapply →

best for: Growth-stage impact companies with measurable IMM.

progress & abundance

Scientific productivity

$1T prize at the limit

The autonomous lab

A PhD spends most of their hours pipetting, not thinking. Build the closed-loop robotic wet-lab that runs experiments 24/7 and proposes the next one.

Why now

Lab robotics + foundation models crossed the line where the design-build-test-learn loop can close without a human in the inner loop.

The shape of it

A self-driving lab as a service: researchers submit hypotheses, the system designs, executes, and iterates experiments autonomously, returning results and next-best experiments.

Success looks like

Experimental throughput per scientist rises an order of magnitude in adopting fields.

good quest

A robotics + ML + lab-science frontier that compounds across all of science; unambiguously good.

The replication layer

Most published findings are never independently checked, so the literature quietly rots. Build the company that makes high-value replication fast, funded, and a default step.

Why now

Autonomous labs + AI literature analysis make systematic replication economically feasible for the first time.

The shape of it

A replication-as-a-service org funded by journals, funders, and firms that need a result to be true before they bet on it; outputs a trust score the field actually uses.

Success looks like

High-stakes results carry a replication status, and the replication rate of new work rises measurably.

good quest

A metascience frontier with leverage over every downstream bet; unambiguously good.

Fast grants as a standing product

It takes 6–12 months to fund a science idea. Fast Grants proved it can take 48 hours without quality loss. Build the always-on micro-grant rail for frontier research.

Why now

The Fast Grants experiment produced the playbook; no one operationalized it as durable infrastructure.

The shape of it

A funding platform with rolling micro-grants, expert triage, and radically compressed decision latency, capitalized by philanthropies and firms wanting optionality on frontier work.

Success looks like

Time from research idea to funded work drops from quarters to days as a standing option.

good quest

An institution-design frontier with outsized leverage; unambiguously good.

Where to apply

1517 Fund · Medici ProjectGrantapply →

best for: Unproven people with a weird, specific idea and no credential path.

best for: Students, dropouts, and renegade builders with a prototype and no credentials, based in North America.

O'Shaughnessy FellowshipsFellowshipapply →

best for: Under-22 builders with spiky talent and a real project.

best for: Agency-specific builders whose project does not fit a discipline box.

hard tech

Longevity & aging

$3T prize at the limit

Aging as an FDA-recognized indication

You cannot run a trial for a disease the regulator does not recognize. Build the company that runs the TAME-class trial and operationalizes aging biomarkers as approvable endpoints.

Why now

Biomarker science (epigenetic and proteomic clocks) matured enough to be candidate endpoints; the regulatory path is the remaining frontier.

The shape of it

A clinical-stage company designing and running the pivotal trial plus the regulatory-science work to make "aging" a legitimate, reimbursable indication.

Success looks like

Aging is a recognized indication with at least one approved intervention and validated endpoints.

good quest

A regulatory + biomarker frontier that unlocks the entire longevity field; unambiguously good if healthspan, not just lifespan, is the target.

The healthspan diagnostic

Medicine measures disease, not the slope of decline. You cannot manage what you do not measure. Build the longitudinal aging-clock and intervention-tracking company.

Why now

Multi-omic aging clocks became reproducible enough to track individual trajectories over time.

The shape of it

A consumer + clinical diagnostic that measures biological aging longitudinally and quantifies whether an intervention is bending the curve.

Success looks like

Individuals and trials can see, in months, whether an intervention slows aging.

good quest

A measurement frontier that makes the whole field falsifiable; unambiguously good.

Where to apply

best for: Unproven people with a weird, specific idea and no credential path.

Deep Science VenturesVenture Studioapply →

best for: Under-22 builders with spiky talent and a real project.

best for: Founders who want a co-founder thesis and institutional support from day one.

Founders FundVenture Capitalapply →

best for: Scaling massive hard-tech quests, space, defense, biotech, fusion.

emerging

Fertility decline & demographic stagnation

$200B prize at the limit

Order-of-magnitude cheaper IVF

Assisted reproduction is gated by cost and clinic throughput, not desire. Build the automated fertility lab that drops the cost of a cycle by an order of magnitude.

Why now

Lab automation + imaging AI can now standardize the most labor-intensive, operator-variable steps of the embryology lab.

The shape of it

An automated embryology platform + clinic model that turns a boutique, artisanal process into a standardized, high-throughput one.

Success looks like

A cycle costs what a used car costs, not what a house down-payment costs, and throughput multiplies.

good quest

A biotech + automation frontier addressing a demographic problem with century-long consequences; unambiguously good for those who want children.

The cost-of-family-formation attack

Below-replacement fertility is downstream of housing, childcare, and time — not ideology. Build the company that makes the marginal child dramatically cheaper to raise.

Why now

The bottleneck stack (housing cost, childcare labor, logistics) is now individually attackable with software + operations.

The shape of it

An operating company bundling the expensive, time-eating parts of early parenting into a radically cheaper, reliable service — pick the wedge (childcare ops, family housing, logistics) and own it.

Success looks like

In served markets, the all-in marginal cost of the next child falls enough to move revealed preference.

good quest

An operations + policy frontier on a problem most ignore until it is irreversible; good if you believe people should be able to afford the families they want.

Where to apply

best for: Unproven people with a weird, specific idea and no credential path.

emerging

Loneliness & social isolation

$200B prize at the limit

Third places as a business model

We optimized retail and offices and quietly deleted the places people simply *are* together. Build the company that makes the modern third place financially self-sustaining.

Why now

Remote/hybrid work permanently changed where people spend their days; the demand for in-person belonging is unmet and growing.

The shape of it

An operator of third places (not an app) with a unit economic model that does not depend on selling attention — membership, food, programming, or local commerce — and is replicable.

Success looks like

A profitable, repeatable third-place format exists and is expanding, measured by relationships formed, not engagement.

good quest

An operations + social-design frontier on a mortality-grade problem; unambiguously good.

Proximity over feeds

Social software optimized engagement and corroded connection. Build the product whose only success metric is offline relationships formed.

Why now

A generation raised on feeds is actively seeking alternatives; the cultural permission to build anti-engagement social products now exists.

The shape of it

A social product engineered, instrumented, and financed around offline meetups and durable local ties — the opposite of a feed — with a business model that rewards that.

Success looks like

Users form measurably more real-world relationships, and the company is viable without an attention-extraction model.

good quest

A product + incentive-design frontier; good only if it genuinely avoids the engagement trap — which is the quest.

Where to apply

O'Shaughnessy FellowshipsFellowshipapply →

best for: Agency-specific builders whose project does not fit a discipline box.

welfare floor

Extreme poverty

$500B prize at the limit

Graduation-approach cost collapse

BRAC's Ultra-Poor Graduation model is the best-evidenced anti-poverty intervention economists have found — income gains that persist a decade later — but it runs ~$5,000 per household because a scarce human coach must personally visit each family for two years. Build the case-management platform that lets one coach run structured, risk-triaged coaching across several times more households.

Why now

Group coaching already cuts the costliest program component — coaching, ~30% of total cost — by 30-40% without losing contact frequency, per BRAC's own program data, meaning the caseload constraint is now a software problem, not a proven-impossible one.

The shape of it

A field-worker app plus a household-risk triage model that decides which families need weekly in-person coaching versus lighter-touch group or remote check-ins, licensed to the national governments and NGOs already running Graduation at state scale.

Success looks like

Cost per graduated household falls from ~$5,000 toward $1,500-2,000 without losing the measured income effect, unlocking several times more households per aid dollar.

good quest

The single best-evidenced anti-poverty intervention that exists, blocked by a solvable operations frontier rather than an unproven mechanism, with no credible harm.

Anticipatory cash as shared infrastructure

When a drought or flood is forecast days out, the households about to be pushed into extreme poverty still wait for money until after the damage lands, because every anticipatory-action program today rebuilds its own forecast-trigger-payment stack from scratch. Build the shared, licensable infrastructure layer any government or NGO plugs into instead of commissioning a bespoke pilot.

Why now

Anticipatory cash is proven — $1 spent before a disaster saves up to $34 in post-disaster response in a Nepal ROI study — and WFP scaled its anticipatory-action portfolio to 44 countries in two years, yet each program is still a custom build.

The shape of it

A forecast-ingestion, trigger-definition, and payment-disbursement API that a Start Network member, government social registry, or small local NGO integrates in weeks instead of running a multi-year pilot, sold as infrastructure-as-a-service rather than run as one more fund.

Success looks like

Standing up a new anticipatory-cash corridor for a new hazard or country drops from years to weeks, and NGOs too small to build their own stack can still offer it.

good quest

A real distribution/software frontier under an intervention already proven to work, decisive for the poorest households facing climate shocks, unambiguously good.

Where to apply

No funder mapped to this quest yet — that’s the white space. browse the full capital stack →

welfare floor

Climate change

$1T prize at the limit

Making natural hydrogen actually flow

Wells worldwide now confirm hydrogen seeping from the earth's crust for free — zero-carbon fuel and fertilizer feedstock with no electrolysis needed. Every current player is a prospector leasing land and drilling wildcats; nobody has solved the real production problem, sustaining commercial flow rates once hydrogen is found. Build the reservoir-stimulation and continuous-extraction technology that turns a discovery well into a production field.

Why now

The USGS's first national geologic hydrogen resource assessment (Jan 2025) reclassified natural hydrogen from curiosity to quantifiable resource, and over $500M has gone into exploration since (Koloma $300M+, Mantle8's $34M Series A, May 2026) even as funded players openly say they're changing their approach because production, not discovery, is the open problem.

The shape of it

A hydrogen-specific reservoir-engineering company — stimulation techniques, in-situ generation acceleration, continuous gas separation — sold to or partnered with exploration companies that have found hydrogen but cannot yet produce it at scale.

Success looks like

A commercial-scale hydrogen well sustains flow rates comparable to a conventional gas well, proving natural hydrogen as a scalable, zero-carbon energy source.

good quest

A genuine subsurface-engineering frontier — the science of finding it is ahead of the science of producing it — decisive for cheap zero-carbon hydrogen, good with no plausible downside.

Methane capture for the open dump, not the landfill

Rich-world landfills capture their methane and sell it as pipeline gas or power. The fastest-growing source of dump methane — open, unmanaged dumps across the Global South — captures none of it, venting a super-pollutant next to the neighborhoods that live on top of them. Build the low-capex gas-capture retrofit company for open and semi-engineered dumps in fast-urbanizing countries.

Why now

Methane's outsized 20-year warming potency plus the Global Methane Pledge's 2030 target are putting a growing bounty on verified methane destruction just as voluntary carbon markets start paying for it, while waste volumes in low- and middle-income countries are rising faster than anywhere else.

The shape of it

Modular, low-cost gas-collection wells and flaring/generation units retrofittable onto existing open dumps without a full landfill rebuild, financed by methane-destruction carbon credits plus local power sales.

Success looks like

Methane capture becomes standard at the world's largest open dumps the way it already is at engineered US/EU landfills, cutting a major uncounted source of near-term warming.

good quest

An engineering + carbon-finance frontier attacking a real, currently near-zero-capture emissions source, with a direct local health co-benefit and no credible harm.

Where to apply

No funder mapped to this quest yet — that’s the white space. browse the full capital stack →

welfare floor

Neglected tropical diseases

$20B prize at the limit

Building the cure, not just the pill, for river blindness

Onchocerciasis has been controlled by an annual ivermectin pill for 30 years because ivermectin only kills the juvenile worms, not the adults — so 200 million people at risk take a drug forever instead of being cured. A macrofilaricide now in Phase II could kill the adult worms outright, but nobody has built the low-cost generic manufacturing and last-mile distribution system to actually deliver a cure once it's approved.

Why now

DNDi and Bayer's emodepside — the first drug shown to kill adult O. volvulus worms, not just microfilariae — cleared Phase II part 1 with a favorable safety and efficacy profile, with Part 2 recruitment starting Q3 2026.

The shape of it

A generic-manufacturing and mass-drug-administration-ready distribution company built now, in partnership with DNDi's access commitments, so approval doesn't sit for years waiting on a manufacturer and delivery network the way it has for other neglected-disease drugs.

Success looks like

Within a few years of approval, endemic communities move from lifelong annual dosing to a course of treatment that actually cures onchocerciasis.

good quest

A genuine translate-the-science-to-the-population frontier — the hard part left is manufacturing and distribution, not biology — decisive for 200M+ people, unambiguously good.

Broad-spectrum antivenom, manufactured at scale

Snakebite kills roughly 100,000 people a year and permanently disables hundreds of thousands more, and standard treatment is still 19th-century technology — antivenom raised in horses, species-specific, expensive, needing a cold chain that doesn't exist where most bites happen. Build the company that takes the newly-proven broadly-neutralizing antibody science to GMP manufacturing and WHO prequalification.

Why now

Within the past few years, researchers have published human monoclonal antibodies and nanobody cocktails that neutralize toxins across whole snake families in animal models, moving broad-spectrum antivenom from theory to demonstrated feasibility for the first time.

The shape of it

A recombinant-antibody manufacturing company that licenses the best-validated broadly-neutralizing antibody cocktails from academic labs and takes them through GMP production, clinical trials, and WHO prequalification, replacing horse serum with a scalable, room-temperature-stable biologic.

Success looks like

A single, room-temperature-stable antivenom treats bites from most medically important snakes in a region without first identifying the species.

good quest

A real biologics-manufacturing frontier against a WHO-listed neglected disease that kills as many people as some infectious epidemics, with no plausible misuse.

Where to apply

No funder mapped to this quest yet — that’s the white space. browse the full capital stack →

welfare floor

Newborn survival

$30B prize at the limit

A sepsis risk score that needs no new hardware

Neonatal sepsis can kill within hours, but the confirmatory test — a blood culture — takes two to three days, so frontline low-resource facilities either over-treat every newborn with antibiotics or miss the ones who needed them. Skip the hardware race and ship the software: a validated risk-prediction model that runs on vital signs facilities already collect, with no new lab or device required.

Why now

Published multivariable and machine-learning models already predict early-onset neonatal sepsis risk from routine low-resource-setting data with real accuracy, and modeling shows a working point-of-care approach could save 100,000-280,000 newborn lives while cutting unnecessary antibiotic use by more than half — the missing piece is a deployed product, not more science.

The shape of it

A lightweight risk-scoring app that ingests the vitals and basic exam data community health workers and low-resource maternity wards already record, flags high-risk newborns for referral or treatment, and requires zero new hardware or lab infrastructure.

Success looks like

Frontline low-resource facilities triage sepsis risk accurately without a lab, cutting both missed cases and antibiotic overuse.

good quest

A genuine deployment-and-validation-at-scale frontier sitting on top of published, unshipped science, decisive for a top-3 cause of newborn death, unambiguously good.

Where to apply

No funder mapped to this quest yet — that’s the white space. browse the full capital stack →

hard tech

AI datacenter power

$400B prize at the limit

Behind-the-meter battery storage for datacenter power smoothing

GPU cluster load spikes whipsaw the grid in a way ordinary datacenter loads never did. Build the fast-response battery system purpose-built for that exact transient signature, not adapted grid-scale arbitrage storage.

Why now

FERC's co-location rules for behind-the-meter storage at datacenters were still being written as of 2026 — the regulatory window is open now, not closed, and no player has captured this specific niche yet.

The shape of it

A battery-plus-power-electronics company selling fast-response, GPU-cluster-tuned smoothing systems directly to hyperscalers and colocation operators, distinct from general grid-scale storage.

Success looks like

Datacenter operators treat GPU-cluster power smoothing as a standard purchased line item, the way they already buy UPS systems, and this company is the default vendor.

good quest

A real systems-engineering frontier sitting at the exact chokepoint under the AI buildout, genuinely still open as of 2026, good with no plausible misuse.

Where to apply